| Literature DB >> 29543839 |
Winnie Wing Yan Yuen1, Albert Lee2, Paul K S Chan3, Lynn Tran1, Erica Sayko1.
Abstract
The present study is aimed at assessing the feasibility of delivering the HPV (human papillomavirus) vaccine to girls through a school-based program in Hong Kong, as well as to examine the facilitators and barriers associated with their participation. We approached 1,229 eligible girls aged 9 to 14 at eight schools in Hong Kong to join the program and then delivered the bivalent HPV vaccine at 0 and 6 months over the course of one school year. The students and their parents completed separate questionnaires to indicate their decision on whether or not to participate, and to assess their knowledge of cervical cancer and the HPV vaccine. The overall vaccine uptake was 81.4% (1,000/1,229) for the first dose and 80.8% (993/1,229) for the second dose. Parents and students were given separate questionnaires and asked whether or not they would like to participate in the vaccination program. 87.1% (1,010/1,160) of parents and 84.9% (974/1,147) of students indicated that they would join the program. The reasons associated with parents' decision not to vaccinate their daughters primarily included concerns around side effects and safety. Multivariate regression analysis showed that parents who thought that the vaccine would protect their daughter from getting cervical cancer (OR = 3.16, 95% CI = 1.39-7.15, p < .01), and those who reported having a doctor's recommendation (OR = 4.54, 95% CI = 1.05-19.57, p < .05) were more likely to join the program. In contrast, parents who had never heard of the vaccine (OR = .15, 95% CI = .03-.71, p < .02), those who were willing to pay more than HK$2,000 for the vaccine (OR = .39, 95% CI = .19-.81, p < .05), or had a preference to access it through a private clinic (OR = .44, 95% CI = .26-.75, p < .01) were significantly less likely to allow their daughter to join the program. Delivery of the HPV vaccine with high uptake rate in a school setting is feasible in Hong Kong. Engaging key stakeholders including school administrators, teachers and community physicians, and providing relevant information on safety and vaccine effectiveness to parents were important to the success of the program.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29543839 PMCID: PMC5854366 DOI: 10.1371/journal.pone.0194159
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Flow chart—HPV vaccination program and research study.
Demographics of the parents as compared to the statistics from the Hong Kong census and statistics department [14].
| % | % from census | ||
|---|---|---|---|
| Male | 123 | 11.0 | NA |
| Female | 998 | 89.0 | NA |
| Parents | 1066 | 94.8 | NA |
| Relatives | 33 | 3.0 | NA |
| Guardian / others | 25 | 2.2 | NA |
| Below 30 | 27 | 2.4 | NA |
| 31–40 | 512 | 45.9 | NA |
| 41–50 | 495 | 44.4 | NA |
| 51 or above | 81 | 7.3 | NA |
| Below 10,000 | 197 | 18.1 | 20.4 |
| 10,000 to <20,000 | 433 | 39.6 | 21.9 |
| 20,000 to < 30,000 | 208 | 19.0 | 17.6 |
| 30,000 or above | 256 | 23.4 | 40.0 |
| Primary or below | 118 | 10.6 | 19.6 |
| Secondary | 885 | 79.8 | 50.5 |
| Tertiary or above | 106 | 9.6 | 29.8 |
Factors reported by parents to be influential in their decision-making.
| Level of influence | ||||
|---|---|---|---|---|
| Not at all influential | Not influential | Influential | Extremely influential | |
| Program is organized by school | 168 (17.3) | 316 (32.6) | 370 (38.1) | 116 (12.0) |
| Program is recommended by the university | 154 (16.2) | 373 (39.1) | 328 (34.4) | 98 (10.3) |
| Effective prevention of cervical cancer | 99 (10.2) | 150 (15.5) | 417 (43.1) | 302 (31.2) |
| HPV vaccine is safe | 97 (10.4) | 171 (18.3) | 412 (44.0) | 256 (27.3) |
| Vaccination is free of charge | 131 (13.9) | 232 (24.5) | 380 (40.2) | 202 (21.4) |
| HPV vaccine is recommended by doctor(s) | 125 (13.5) | 290 (31.4) | 388 (42.0) | 121 (13.1) |
| Fear of possible side effects | 11 (8.7) | 27 (21.3) | 66 (52.0) | 23 (18.1) |
| Doubt the effectiveness of vaccine | 11 (8.9) | 55 (44.7) | 48 (39.0) | 9 (7.3) |
| Lacking doctor’s recommendation | 16 (13.4) | 52 (43.7) | 47 (39.5) | 4 (3.4) |
| Lacking government’s recommendation | 13 (11.0) | 68 (57.6) | 34 (28.8) | 3 (2.6) |
| Worried others might think daughter is sexually active | 41 (34.5) | 66 (55.5) | 11 (9.2) | 1 (0.8) |
| Worried that daughter will start having sex earlier if vaccinated | 42 (35.0) | 63 (52.5) | 13 (10.8) | 2 (1.7) |
Factors reported by students to be influential in their decision-making.
| Level of influence | ||||
|---|---|---|---|---|
| Not at all influential | Not influential | Influential | Extremely influential | |
| This program is organized by school | 265 (27.7) | 319 (33.4) | 286 (29.9) | 86 (9) |
| This program is recommended by university | 245 (26.1) | 397 (42.3) | 240 (25.6) | 57 (6.1) |
| Vaccine can effectively prevent cervical cancer | 162 (16.8) | 143 (14.8) | 350 (36.3) | 310 (32.1) |
| Vaccine is safe | 157 (16.7) | 180 (19.1) | 358 (38.0) | 246 (26.1) |
| Free vaccination | 216 (22.8%) | 209 (22.1) | 297 (31.4) | 225 (23.8) |
| Doctor’s recommendation | 239 (25.7) | 315 (33.8) | 269 (28.9) | 108 (11.6) |
| Parents’ or family members’ recommendation | 194 (20.6) | 257 (27.2) | 327 (34.6) | 166 (17.6) |
| Classmates/friends join the program | 271 (28.9) | 320 (34.2) | 267 (28.5) | 79 (8.4) |
| Possible side effects | 24 (19.4) | 45 (36.3) | 42 (33.9) | 13 (10.5) |
| Doubt the effectiveness of vaccine | 26 (21.1) | 54 (43.9) | 35 (28.5) | 8 (6.5) |
| Absence of doctor’s recommendation | 31 (25.0) | 58 (46.8) | 29 (23.4) | 6 (4.8) |
| Absence of government recommendation | 35 (28.7) | 68 (55.7) | 15 (12.3) | 4 (3.3) |
| Objection from parents/family members | 18 (14.3) | 43 (34.1) | 45 (35.7) | 20 (15.9) |
| Classmates/friends have not joined | 42 (34.7) | 54 (44.6) | 20 (16.5) | 5 (4.1) |
| Worry that vaccine may affect their growth | 27 (2.4) | 59 (48.4) | 26 (21.3) | 10 (8.2) |
| Fear of pain from injection | 29 (23.8) | 53 (43.4) | 25 (20.5) | 15 (12.3) |
Comparison between parents who allowed their children to join and not join the HPV vaccination program (univariate regressions).
| OR | 95% CI | ||||
|---|---|---|---|---|---|
| No | Yes | ||||
| Doctor | 19 (15.8%) | 199 (19.9%) | 1.32 | .79–2.21 | .29 |
| School | 45 (37.5%) | 360 (36.1%) | 0.94 | .64–1.39 | .94 |
| Poster | 70 (58.3%) | 571 (57.1%) | 0.96 | .65–1.40 | .41 |
| Media | 93 (77.5%) | 805 (80.7%) | 1.21 | .77–1.91 | .41 |
| Friends / relatives | 20 (16.7%) | 185 (18.5%) | 1.14 | .69–1.89 | .62 |
| Never heard of HPV | 5 (4.2%) | 12 (1.2%) | 0.28 | .10 –.81 | 0.02 |
| 1.09 | .99–1.21 | .08 | |||
| Cervical cancer is common ( | 84 (80.8%) | 854 (89.3%) | 1.99 | 1.17–3.38 | .01 |
| Early stage cervical cancer is treatable ( | 83 (79.0%) | 830 (86.9%) | 1.76 | 1.06–2.92 | .03 |
| Cervical cancer may affect fertility ( | 81 (77.1%) | 786 (82.6%) | 1.40 | .86–2.28 | .17 |
| Increase risk with multiple sex partners ( | 76 (72.4%) | 701 (73.8%) | 1.07 | .68–1.69 | .76 |
| Women have a fair chance of contracting HPV ( | 53 (50.5%) | 502 (52.8%) | 1.10 | .74–1.65 | .65 |
| Pap smears can prevent cervical cancer ( | 61 (58.7%) | 616 (64.8%) | 1.30 | .86–1.96 | .21 |
| Cervical cancer is caused by viral infection ( | 76 (73.1%) | 625 (65.7%) | .71 | .45–1.11 | .13 |
| A woman dies of cervical cancer every 3 days ( | 33 (32.0%) | 448 (47.0%) | 1.88 | 1.22–2.90 | .004 |
| .91 | .73–1.14 | .41 | |||
| Waist pain | 88 (88.9%) | 748 (80.7%) | .52 | .27–1.00 | 0.05 |
| Fear of cold | 96 (97.0%) | 874 (94.3%) | .52 | .16–1.68 | .52 |
| Abnormal bleeding between menses | 79 (79.8%) | 726 (78.3%) | .91 | .55–1.53 | .73 |
| Breast pain | 89 (89.9%) | 810 (87.4%) | .78 | .39–1.54 | .47 |
| Bleeding after sexual intercourse | 64 (64.6%) | 658 (71.0%) | 1.34 | .87–2.07 | .19 |
| 1.45 | .92–2.27 | .11 | |||
| Should not receive before their first menstruation | 92 (90.2%) | 867 (92.2%) | 1.29 | .64–2.59 | .47 |
| Ideal vaccination time is before the first time having sex | 70 (68.6%) | 615 (65.4%) | .87 | .56–1.34 | .52 |
| HPV vaccination can prevent all STIs | 96 (94.1%) | 842 (89.6%) | .54 | .23–1.26 | .15 |
| HPV vaccination would not affect growth | 64 (62.7%) | 742 (78.9%) | 2.23 | 1.45–3.42 | < .001 |
| Females who are sexually active can still receive HPV vaccine to prevent future infection | 61 (59.8%) | 645 (68.6%) | 1.17 | .98–1.40 | .09 |
| My daughter will be infected by HPV ( | 49 (52.1%) | 435 (47.3%) | .83 | .54–1.26 | .38 |
| My daughter will get cervical cancer ( | 44 (47.8%) | 448 (48.7%) | 1.04 | .68–1.60 | .87 |
| Getting cervical cancer will affect my daughter tremendously ( | 87 (89.7%) | 886 (95.3%) | 2.32 | 1.13–4.76 | .02 |
| HPV vaccine protects my daughter from HPV infection ( | 78 (81.3%) | 889 (94.3%) | 3.80 | 2.12–6.80 | < .001 |
| Perceived sufficient understanding of HPV vaccine ( | 27 (26.2%) | 213 (22.4%) | 1.23 | .77–1.96 | .38 |
| Doctor recommended before ( | 4 (3.8%) | 106 (11.1%) | 3.17 | 1.43–8.78 | .03 |
| Has regular family doctor ( | 51 (47.7%) | 352 (36.3%) | .63 | .42 –.93 | .02 |
| Received all vaccines at Department of Health ( | 74 (74.0%) | 728 (75.8%) | 1.10 | .69–1.76 | .70 |
| Mother had a pap smear in the past 3 years ( | 65 (61.3%) | 537 (56.2%) | 0.81 | .54–1.22 | .31 |
| Mother received HPV vaccination ( | 10 (9.7%) | 94 (9.8%) | 1.01 | .51–2.01 | .97 |
| Government should provide HPV vaccine to boys & girls ( | 38 (37.6%) | 312 (32.8%) | .81 | .53–1.24 | .33 |
| Willing to pay more than HK$2,000 for HPV vaccine ( | 18 (18.8%) | 76 (8.0%) | .38 | .21 –.66 | .001 |
| Preferred location—maternal and child health centers ( | 64 (62.1%) | 580 (60.8%) | .95 | .62–1.44 | .79 |
| Preferred location—private clinics ( | 48 (46.6%) | 295 (30.9) | .51 | .34 –.77 | .001 |
| Preferred location–schools ( | 48 (46.6%) | 561 (58.8%) | 1.64 | 1.09–2.46 | .02 |
| Watched educational video ( | 20 (19.4%) | 232 (24.3%) | 1.34 | .80–2.22 | .27 |
| 99 (93.4%) | 858 (88.5%) | .54 | .25–1.20 | .13 | |
| 61 (58.7%) | 495 (51.2%) | .74 | .49–1.12 | .15 | |
| 96 (92.3%) | 861 (89.6%) | .72 | .34–1.52 | .39 | |
| 33 (32.7%) | 216 (22.7%) | .61 | .39 –.94 | .03 | |
* = significant at p
** = significant at p< .01.
*** = significant at p
Analyses of factors associated with parents’ decision-making using multivariate logistic regression (n = 857).
| OR | 95% CI | ||
|---|---|---|---|
| .15 | .03-.71 | .02 | |
| .92 | .67–1.26 | .60 | |
| Cervical cancer is common | 1.38 | .57–3.32 | .48 |
| Early stage cervical cancer is treatable | 1.09 | .46–2.62 | .84 |
| Cervical cancer may affect fertility | 1.38 | .62–3.09 | .43 |
| Cervical cancer is caused by viral infection | 0.64 | .28–1.42 | .27 |
| A woman dies of cervical cancer every 3 days | 1.74 | .90–3.38 | .10 |
| 0.43 | 0.17–1.06 | .07 | |
| 1.28 | .71–2.32 | .42 | |
| 1.07 | .50–2.28 | .86 | |
| HPV vaccine prevents all STIs | .49 | .16–1.50 | .21 |
| HPV vaccine would not affect growth | 1.82 | .95–3.51 | .07 |
| Females who have had sex can still receive HPV vaccine to prevent future infection | 1.42 | .73–2.76 | .31 |
| 2.03 | .76–5.40 | .16 | |
| 3.16 | 1.39–7.15 | .006 | |
| 4.54 | 1.05–19.57 | .04 | |
| .75 | .43–1.30 | .30 | |
| .39 | .19-.81 | .01 | |
| .44 | .26-.75 | .002 | |
| 1.44 | .85–2.45 | .17 | |
| .41 | .12–1.37 | .15 | |
| .77 | .45–1.61 | .33 | |
| .56 | .31–1.02 | .06 |
* = significant at p
** = significant at p< .01.
Comparison between students who participated and who did not participate in the program (univariate regressions).
| Joined program | OR | 95% CI | |||
|---|---|---|---|---|---|
| No | Yes | ||||
| Doctor | 37 (32.7%) | 345 (39.5%) | 1.34 | .88–2.03 | .17 |
| School | 52 (46.0%) | 466 (53.3%) | 1.34 | .90–1.99 | .15 |
| Parents | 32 (28.3%) | 372 (42.6%) | 1.88 | 1.22–2.89 | .004 |
| Media | 5 (4.4%) | 39 (4.5%) | 1.01 | .39–2.62 | .99 |
| Friends / relatives | 20 (17.7%) | 167 (19.1%) | 1.10 | .66–1.83 | .72 |
| Never heard of HPV | 11 (9.7%) | 77 (8.8%) | .90 | .46–1.74 | .75 |
| It is a fatal disease ( | 79 (71.8%) | 697 (76.8%) | 1.30 | .83–2.02 | .25 |
| Early stage of cervical cancer is treatable ( | 64 (56.6%) | 596 (65.9%) | 1.48 | .99–2.20 | .05 |
| It is one of the common cancers found in women in HK ( | 83 (74.8%) | 750 (82.5%) | 1.59 | 1.00–2.52 | .048 |
| HPV vaccine can prevent cervical cancer ( | 71 (63.4%) | 798 (88.0%) | 4.23 | 2.74–6.52 | <.001 |
| Females still need to have Pap’s smears regularly after HPV vaccine ( | 58 (51.8%) | 473 (52.3%) | 1.02 | .69–1.51 | .92 |
| Smoking is a risk factor | 37 (32.5%) | 375 (41.0%) | 1.45 | .96–2.19 | .08 |
| Having multiple sex partners is a risk factor | 80 (69.6%) | 575 (62.8%) | .74 | .49–1.13 | .16 |
| Not enough sleep is a risk factor | 20 (17.4%) | 136 (14.9%) | .83 | .50–1.39 | .48 |
| Prior pregnancy is a risk factor | 30 (26.1%) | 258 (28.2%) | 1.11 | .72–1.73 | .64 |
| Started sex early is a risk factor | 60 (52.2%) | 542 (59.2%) | 1.33 | .90–1.97 | .15 |
| 82 (75.9%) | 756 (84.6%) | 1.74 | 1.08–2.80 | .02 | |
| 77 (74.0%) | 635 (75.8%) | 1.10 | .69–1.75 | .70 | |
| 40 (38.5%) | 334 (40.0%) | 1.07 | .70–1.62 | .76 | |
| 62 (60.8%) | 553 (65.7%) | 1.24 | .81–1.88 | .33 | |
* = significant at p
** = significant at p< .01.
*** = significant at p
Analyses of students’ factors associated with joining the program using multivariate logistic regression (n = 928).
| OR | 95% CI | ||
|---|---|---|---|
| Doctor | 1.27 | .79–2.04 | .32 |
| School | 1.22 | .78–1.90 | .39 |
| Parents | 1.97 | 1.22–3.16 | .005 |
| Early stage of cervical cancer is treatable | 1.16 | .73–1.85 | .54 |
| It is one of the common cancers found in women in HK | 1.30 | .75–2.23 | .35 |
| HPV vaccine can prevent cervical cancer | 3.94 | 2.35–6.60 | <0.001 |
| Smoking is a risk factor | 1.62 | .10–2.64 | .052 |
| Having multiple sex partners is a risk factor | .51 | .31-.84 | .009 |
| Started sex early is a risk factor | 1.60 | 1.00–2.54 | .050 |
| 1.24 | .73–2.11 | .43 |
* = significant at p< .01.
** = significant at p